Medical Advocates
Nevirapine (Viramune)
 
Journal Citations

General Reports
 Animal Studies
Formulations/Dosing           
Safety/Tolerability
 Pharmacokinetics      
Drug/Drug Interactions
 Resistance
Viral Dynamics
Diagnostics/Monitoring
 Adverse Events
 Efficacy
 Adolescent/Adult Treatment
Therapeutic Strategies 
 Special Populations 
Investigator Interviews





 
NVP Main Page  Main New/Newsworthy 

Home Page

  

 

  
Last Update:  February 04, 2012
 Perinatal Journal Data are in the Perinatal Data Page
Pediatric Journal Data are in the Pediatric Data Page
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 
Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive
Patients Using Dried Sample Spot Devices.
 Calcagno A, D'Avolio A, Simiele M,  et al
Br J Clin Pharmacol. 2011 Dec 22.
 Abstract

Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion.
Burke EW, Morris GA, Vincent MA, et al
Org Biomol Chem. 2011 Dec 12.
 Abstract

Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation.
 Shegokar R, Singh KK.
Int J Pharm. 2011 Oct 1
 Abstract

Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted
poly(lactide-co-glycolide) nanoparticles.
Kuo YC, Lin PI, Wang CC.
 Nanomedicine (Lond). 2011 Jun 27
 Abstract

Nevirapine nanosuspensions for HIV reservoir targeting.
 Shegokar R, Singh KK.
Pharmazie. 2011 Jun;66(6):408-15.
 Abstract

Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted
poly(lactide-co-glycolide) nanoparticles.
 Kuo YC, Lin PI, Wang CC.
Nanomedicine (Lond). 2011 Jun 27
 Abstract

Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression,
and release of adipokines and cytokines.
 Díaz-Delfín J, Del Mar Gutiérrez M, Gallego-Escuredo JM,  et al
Antiviral Res. 2011 May 17.
Abstract

FULL-TEXT PDF ARTICLE
 Development of a liposomal nanodelivery system for nevirapine.
 Ramana LN, Sethuraman S, Ranga U, Krishnan UM.
J Biomed Sci. 2010 Jul 13;17(1):57
 Paper

FULL-TEXT PDF ARTICLE
 N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward
RNase H cleavage during plus-strand initiation.
 Biondi MJ, Beilhartz GL, McCormick S, Gotte M.
J Biol Chem. 2010 Jun 8
 Paper

Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of
quantum mechanical and force field approaches and predictions of the effect of
mutations on binding.
Raju RK, Burton NA, Hillier IH
 Phys Chem Chem Phys. 2010 May 17
 Abstract

Study on the interaction between HIV reverse transcriptase and its non-nucleoside
inhibitor nevirapine by capillary electrophoresis.
 Chen W, Li W, Ling X, Wang X, Liu J.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Apr 24.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected
patients receiving atazanavir/ritonavir.
 Moltó J, Deig E, Valle M,  et al 
Ther Drug Monit. 2010 Feb;32(1):93-6.
 Abstract

Simultaneous production and co-mixing of microparticles of nevirapine with excipients
by supercritical antisolvent method for dissolution enhancement.
Sanganwar GP, Sathigari S, Babu RJ, Gupta RB.
Eur J Pharm Sci. 2009 Dec 2.
 Abstract

Assessment of Nevirapine Bioavailability From Targeted Sites in the Human Gastrointestinal Tract.
 Macha S, Yong CL, Macgregor TR, et al 
J Clin Pharmacol. 2009 Sep 30.
 Abstract

FULL-TEXT ARTICLE
 Metabolic Activation of Nevirapine in Human Liver Microsomes: Dehydrogenation and Inactivation of
Cytochrome P450 3A4.
 Wen B, Chen Y, Fitch WL.  
 Drug Metab Dispos. 2009 Apr 13
 Paper

Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells.
 Stefanidis K, Loutradis D, Vassiliou LV, et al 
Gynecol Oncol. 2008 Sep 24.
 Abstract
 
Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.
 Streck EL, Scaini G, Rezin GT, et al 
Metab Brain Dis. 2008 Sep 24.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and
co-medication.
 Stöhr W, Back D, Dunn D, et al
Antivir Ther. 2008;13(5):675-85.
 Abstract
 
Synthesis and Characterization of DNA Adducts from the HIV Reverse Transcriptase Inhibitor Nevirapine.
 Antunes AM, Duarte MP, Santos PP, et al 
Chem Res Toxicol. 2008 Jul 3
 Abstract
 
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma
concentrations in HIV-infected patients.
 Wyen C, Hendra H, Vogel M, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of
residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.
 Kroeger Smith MB, Rader LH, et al   
 Bioorg Med Chem Lett. 2007 Dec 23
Abstract
 
Synthesis and anti-HIV activity of nevirapine prodrugs.
 Sriram D, Yogeeswari P, Kishore MR.
 Pharmazie. 2006 Nov;61(11):895-7
 Abstract
 
Enzyme Inducers Reduce Elimination Half-Life After a Single Dose of Nevirapine in Healthy
Women.
 L'homme RF, Dijkema T, van der Ven AJ, Burger DM
J Acquir Immune Defic Syndr. 2006 Aug 24;
 Abstract
 
The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz
in the treatment of patients with a chronic HIV-I infection
 van Leth F, Lange JM. 
Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22
 Abstract

Nevirapine derivatives with broad-spectrum chemotherapeutic properties for the effective
treatment of HIV/AIDS.
 Sriram D, Srichakravarthy N, Bal TR, Yogeeswari P. 
Biomed Pharmacother. 2005 Sep;59(8):456-9.
Abstract
Animal Studies
 
 
Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats.
Adaramoye OA, Adesanoye OA, Adewumi OM, Akanni O.
Hum Exp Toxicol. 2011 Oct 25
Abstract

Bioavailability of nevirapine in rats after oral and subcutaneous administration, in vivo absorption from
gastrointestinal segments and effect of bile on its absorption from duodenum.
 Usach I, Peris JE.
Int J Pharm. 2011 Aug 6.
Abstract

Anti-HIV Drugs Nevirapine and Efavirenz Affect Anxiety-Related Behavior and Cognitive
Performance in Mice.
Romão PR, Lemos JC, Moreira J, et al
Neurotox Res. .
 Abstract

RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced
hepatotoxicity.
 Walubo A, Barr S, Abraham AM.
Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
 Abstract
Formulations/Dosing
 
 
Nevirapine extended-release for the treatment of HIV-1 infection.
Bogner JR.
Expert Rev Anti Infect Ther. 2012 Jan;10(1):21-30.
 Abstract

Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine
immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
 Arasteh K, Ward D, Plettenberg A, et al 
HIV Med. 2011 Dec 4.
Abstract

Guidelines for the use of extended-release nevirapine in HIV-infected patients.
Heil EL, Corbett AH.
 Expert Opin Pharmacother. 2011 Oct 29
 Abstract

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated
Tuberculosis: A Randomized Clinical Trial.
 Swaminathan S, Padmapriyadarsini C, Venkatesan P,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1:
A Multicenter, Open-Label Study.
 Battegay PM, Arasteh DK, Plettenberg DA, et al
Clin Ther. 2011 Aug 26.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release
twice-daily in treatment-naive HIV-1-infected patients.
 Gathe J, Andrade-Villanueva J, Santiago S, et al
 Antivir Ther. 2011;16(5):759-69.
 Abstract

FULL-TEXT ARTICLE
 Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose
lection in HIV-infected individuals.
 Schipani A, Wyen C, Mahungu T, et al
J Antimicrob Chemother. 2011 Mar 25
 Paper

Once- or twice-daily dosing of nevirapine in HIV-infected adults:
a population pharmacokinetics approach.
Moltó J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract

Once-daily dosing of nevirapine in HAART.
Clotet B.
 J Antimicrob Chemother. 2007 Nov 14;
Abstract

Bioequivalence study of two nevirapine tablet formulations in human immunodeficiency
virus-infected patients
Tarinas A, Tápanes RD, González D, et al
Farm Hosp. 2007 Jun;31(3):165-168.
 Abstract
Safety/Tolerability
 
 
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K, Ward D, Plettenberg A, et al 
HIV Med. 2011 Dec 4.
Abstract

Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC, Rockstroh JK, Hardy WD.
Expert Opin Drug Saf. 2011 Nov 26
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with z
idovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
 Dart Trial Team 
Trop Med Int Health. 2008 Jan;13(1):6-16.
 Abstract
Pharmacokinetics
           
 
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
Svensson E, van der Walt JS, Barnes KI, et al
Br J Clin Pharmacol. 2012 Feb 2.
 Abstract

Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected Sub-Saharan
African Women.
Dong BJ, Zheng Y, Hughes MD, et al
AIDS. 2012 Feb 1
 Abstract

Population Pharmacokinetics of Nevirapine in HIV-1 infected Pregnant Women and their
neonates (ANRS 12109).
Benaboud S, Ekouévi DK, Urien S, et al
Antimicrob Agents Chemother. 2010 Oct 18
 Abstract

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected
Cambodian patients (ANRS12154).
Chou M, Bertrand J, Segeral O, Verstuyft C, et al
Antimicrob Agents Chemother. 2010 Aug 9
 Abstract

Pharmacokinetic Assessment of Nevirapine and Metabolites in HIV-1 Patients with
Hepatic Fibrosis.
 Cammett AM, Macgregor TR, Wruck JM, et al  
 Antimicrob Agents Chemother. 2009 Jul 20.
 Abstract

Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
 Vogel M, Bertram N, Wasmuth JC, et al
J Antimicrob Chemother. 2009 Mar 6.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
 Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.
 Abstract
 
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant
women and women in late pregnancy.
 von Hentig N, Carlebach A, Gute P, et al
Br J Clin Pharmacol. 2006 Nov;62(5):552-9.
Abstract
 
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency
virus-infected individuals.
 Almond LM, Edirisinghe D, Dalton M, et al 
Clin Pharmacol Ther. 2005 Aug;78(2):132-42
 Abstract
 
Short communication: changes in nevirapine plasma concentrations over time and its
relationship with liver enzyme elevations.
De Requena DG, Jimenez-Nacher I, Soriano V.
AIDS Res Hum Retroviruses. 2005 Jun;21(6):555-9.
Abstract
 
Race Is Not Associated with Nevirapine Pharmacokinetics.
 De Maat MM, Nellen JF, Huitema AD   
Ther Drug Monit. 2004 Aug;26(4):456-458.
 Abstract
 
No relationship between high nevirapine plasma concentration and hepatotoxicity
in HIV-1-infected patients naive of antiretroviral treatment or switched from protease
inhibitors.
 Dailly E, Billaud E, Reliquet V 
Eur J Clin Pharmacol. 2004 May 20
 Abstract

Exposure of normal and transformed cells to nevirapine, a reverse transcriptase
inhibitor, reduces cell growth and promotes differentiation.
Mangiacasale R, Pittoggi C, Sciamanna I, et al.
Oncogene 2003 May 8;22(18):2750-61
 Abstract

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected
individuals.
De Maat MM, Huitema AD, Mulder JW, et al.
Br J Clin Pharmacol 2002 Oct;54(4):378-85
 Abstract

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected
individuals.
De Maat MM, Huitema AD,Mulder JW, et al.
Br J Clin Pharmacol 2002 May;53(5):552P
 Abstract

Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal  plasma.
van Praag RM, Repping S, de Vries JW, et al.
Antimicrob Agents Chemother 2001Oct;45(10):2902-2907
 Abstract

FULL-TEXT ARTICLE
 Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human
immunodeficiency virus-infected patients. The National Institute of Allergy and
Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Zhou XJ, Sheiner LB, D'Aquila RT, et al  
 Antimicrob Agents Chemother 1999
Paper

 		 
Viral Dynamics
 
 
Low Trough Plasma Concentrations of Nevirapine Associated with Virologic
Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors (April).
 Duong M, Buisson M, Peytavin G, et al  
Ann Pharmacother. 2005 Feb 15;
 Abstract
 
Predictors of virologic failure and resistance in HIV-infected patients treated with
nevirapine- or efavirenz-based antiretroviral therapy.
 Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
 Abstract
 
Virologic and Immunologic Response to Regimens Containing Nevirapine or
Efavirenz  in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive
Antiretrovirals (I.Co.N.A. Study)  
Cozzi-Lepri A, Phillips AN, Monforte Ad A, et al.
J Infect Dis 2002 Apr 15;185(8):1062-1069
 Abstract
 
Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by
Nevirapine in Patients With Suppressed Plasma HIV-1 RNA.
Masquelier B, Neau D, Chene G, et al.
J Acquir Immune Defic Syndr 2001 Dec 1;28(4):309-12 
 Abstract
 
Resistance
 
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line
Antiretroviral Treatment:
A Bayesian Analysis
 Ngo-Giang-Huong N,  Jourdain G, Amzal B, et al
PLoS ONE 6(11): e27427
 Paper

A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of
Virological Failure to
Nevirapine Therapy.
 Paredes R, Puertas MC, Bannister W, et al
J Infect Dis. 2011 Sep;204(5):741-752.
 Abstract

Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or
nevirapine/zidovudine prophylaxis.
Fogel J, Hoover DR, Sun J, et al
AIDS. 2011 Apr 24;25(7):911-917.
 Abstract

Estimating Frequencies of Minority Nevirapine Resistant Strains in Chronically HIV-1
Infected Individuals Naive to Nevirapine in Using Stochastic Simulations and a
Mathematical Model
 Gadhamsetty S, Dixit NM
 J Virol. 2010 Jul 28.
 Abstract

Ultrasensitive Detection of Minor Drug-Resistant Variants for HIV After Nevirapine Exposure
Using Allele-Specific PCR: Clinical Significance.
Rowley CF, Boutwell CL, Lee EJ, et al
AIDS Res Hum Retroviruses. 2010 Mar;26(3):293-300
 Abstract

Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus
Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but not to Etravirine.
 Gatanaga H, Ode H, Hachiya A,  et al 
Antimicrob Agents Chemother. 2010 Feb 1
 Abstract

Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic
Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy.
 Geretti AM, Fox ZV, Booth CL,
J Acquir Immune Defic Syndr. 2009 Sep 22
 Abstract

Drug resistance of HIV-1 as a result of using nevirapine for chemoprophylaxis of vertical viral transmission
from HIV-infected mother to infant
 [No authors listed] 
Vopr Virusol. 2009 Jan-Feb;54(1):45-8.
 Abstract
 
Prevalence of Nevirapine-Associated Resistance Mutations after Single Dose Prophylactic
Treatment among Antenatal Clinic Attendees in North Rift Kenya.
 Kiptoo M, Ichimura H, Wembe RL,  et al
AIDS Res Hum Retroviruses. 2008 Dec;24(12):1555-9.
 Abstract
 
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic
resistance after treatment interruption.
 Darwich L, Esteve A, Ruiz L, et al
Antivir Ther. 2008;13(7):945-51.
 Abstract
 
Development of Phenotypic HIV-1 Drug Resistance After Exposure to Single-Dose Nevirapine.
 Basson AE, Ntsala M, Martinson N,et al
J Acquir Immune Defic Syndr. 2008 Nov 4.
 Abstract
 
Bayesian network analyses of resistance pathways against efavirenz and nevirapine.
 Deforche K, Camacho RJ, Grossman Z, et al   
AIDS. 2008 Oct 18;22(16):2107-15.
 Abstract
 
Comparison of genotypic resistance profiles and virological response between patients
starting nevirapine and efavirenz in EuroSIDA.
 Bannister WP, Ruiz L, Cozzi-Lepri A, et al  
AIDS. 2008 Jan 30;22(3):367-76
 Abstract
 
FULL TEXT ARTICLE
 N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine
and Nevirapine Resistance.
 Yap SH, Sheen CW, Fahey J, et al 
PLoS Med. 2007 Dec 1;4(12):e335
Abstract
 
Short Communication: HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely
Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D.
 Church JD, Hudelson SE, Guay LA, et al 
AIDS Res Hum Retroviruses. 2007 Jun;23(6):764-8.
 Abstract
 
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in
HIV-infectedpatients in Uganda.
 Penzak S, Kabuye G, Mugyenyi P, et al 
HIV Med. 2007 Mar;8(2):86-91.
 Abstract
 
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with
nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
 
Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to
nevirapine through point mutations.
 He X, Mei Y, Xiang Y, et al 
Proteins. 2005 Aug 19;
Abstract
 
Novel patterns of nevirapine resistance-associated mutations of human
immunodeficiency virus type 1 in treatment-naive patients.
 Hachiya A, Gatanaga H, Kodama E, et al 
Virology. 2004 Oct 1;327(2):215-24.
Abstract
 
Competitive fitness of nevirapine-resistant human immunodeficiency virus type
1 mutants.
 Collins JA, Thompson MG, Paintsil E, et al 
J Virol. 2004 Jan;78(2):603-11.
 Abstract

FULL-TEXT  PDF ARTICLE
 Nevirapine resistance mutation at codon 181 of the  HIV-1 reverse transcriptase
confers Stavudine resistance by increasing nucleotide substrate discrimination 
and phosphorolytic activity
 Blanca G, Baldanti F, Paolucci S, et al.
J Biol Chem 2003 Feb 24;
 PDF Paper

 Patterns of resistance mutations selected by treatment of human immunodeficiency  
virus type 1infection with zidovudine, didanosine, and nevirapine. 
 Hanna GJ, Johnson VA, Kuritzkes DR et al.                          
Journal of Infectious Disease 2000; 181(3): 904-911.
 Abstract

Resistance profile and cross-resistance of HIV-1 among patients failing a non-
nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C, Rohban R, Simon A. et al.  
 J Med Virol 2001  Nov;65(3):445-8
Abstract

Novel deletion of hiv type 1 reverse transcriptase residue 69 conferring selective
high-level resistance to nevirapine.
 Suzuki K, Kaufmann GR, Mukaide M, et al.
AIDS Res Hum Retroviruses 2001 Sep;17(13):1293-6
 Abstract

 		 
Diagnostics/Monitoring
 
 
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
 Kromdijk W, Mulder JW, Rosing H, et al
J Antimicrob Chemother. 2012 Feb 1
 Abstract

Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem
mass spectrometry.
 Huang Y, Yang Q, Yoon K, et al
Anal Bioanal Chem. 2011 Aug 17
 Abstract

Evidence-based Therapeutic Drug Monitoring for Nevirapine
Muret P, Piedoux S, Solas C, Quaranta S.
 Therapie. 2011 May-Jun;66(3):187-95
 Abstract

FULL-TEXT ARTICLE
 Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple
Approach to HIV-1 Drug-Resistance Testing.
 Hoffmann D, Garcia AD, Harrigan PR, et al
PLoS One. 2011;6(7):e22019.
Paper

Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz.
 Pelet A, Favrat B, Cavassini M,
Am J Drug Alcohol Abuse. 2011 Jul;37(4):264-8
 Abstract

Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving
Nevirapine or Efavirenz.
Pelet A, Favrat B, Cavassini M, et al
 Am J Drug Alcohol Abuse. 2011 Jun 23
 Abstract

Determination of nevirapine in plasma by GC-MS.
 Vogel M, Bertram N, Wasmuth JC, et al
J Chromatogr Sci. 2010 Feb;48(2):91-4.
 Abstract

Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications
of NMR and Mass Spectrometries.
Srivastava A, Lian LY, Maggs JL, et al 
Drug Metab Dispos. 2009 Oct 1.
Abstract

A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine,
indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir
and maraviroc in the plasma of patients infected with HIV.
 Martin J, Deslandes G, Dailly E, et al 
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 3
 Abstract

Therapeutic drug monitoring of nevirapine in resource-limited settings.
L'homme RF, Muro EP, Droste JA, et al
Clin Infect Dis. 2008 Nov 15;47(10):1339-44.
 Abstract
 
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine
concentration in human plasma by MALDI-TOF/TOF.
 Notari S, Mancone C, Alonzi T, et al    
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 16
Abstract
 
An immunochromatographic strip test for the rapid detection of nevirapine in plasma samples of
HIV-infected patients.
 Cressey TR, Nangola S, Tawon Y, et al 
Antimicrob Agents Chemother. 2007 Jul 2
 Abstract
 
A simple and rapid liquid chromatography method for simultaneous determination of
zidovudine and nevirapine  in plasma.
Ramachandran G, Hemanthkumar AK, Kumaraswami V, Swaminathan S.
J tChromatogr B Analyt Technol Biomed Life Sci. 2006 Jun 30;
 Abstract
 
Detection of nevirapine in plasma using thin-layer chromatography.
 Dubuisson JG, King JR, Stringer JS, et al
 J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 155-7.
 Abstract

An LC-MS-MS method for the determination of nevirapine, a non-nucleoside
reverse transcriptase inhibitor, in human plasma.
 Chi J, Jayewardene AL, Stone JA, Aweeka FT.
 Pharm Biomed Anal 2003 Apr 1;31(5):953-99
 Abstract

  
Efficacy
       
General Reports
 
 
FULL-TEXT PDF ARTICLE
 Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected
patients with or without viral hepatitis B or C infection in Cameroon.
 Tchatchueng Mbougua JB, Laurent C, et al
 BMC Public Health. 2010 Mar 1;10(1):105
 Paper

Suboptimal Etravirine Activity is Common During Failure of Nevirapine-based Combination
Antiretroviral Therapy in a Cohort Infected with non-B subtype HIV-1.
 Taiwo B, Chaplin B, Penugonda S, et al  
Curr HIV Res. 2010 Feb 18.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A, Vallier N, Nguyen A, Lange JM,  et al
Antivir Ther. 2009;14(7):931-938.
 Abstract

Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6
Years on Nevirapine.
Rodríguez-Arrondo F, Aguirrebengoa K, et al
Curr HIV Res. 2009 Sep;7(5):526-532
 Abstract

Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
 Colafigli M, Di Giambenedetto S, Bracciale L, et al 
HIV Med. 2009 May 6.
Abstract

Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving
Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin.
 Manosuthi W, Sungkanuparph S, Thakkinstian A, et al
Clin Infect Dis. 2006 Jul 15;43(2):253-5
 Abstract
 
Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected
Patients.
 Bonjoch A, Paredes R, Domingo P, et al  
AIDS Res Hum Retroviruses. 2006 Apr;22(4):321-9.
Abstract

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety
of nevirapine or efavirenz-based first-line HAART.
 van Leth F, Andrews S, Grinsztejn B, Wilkins E
AIDS. 2005 Mar 25;19(5):463-471
 Abstract

NVP vs ATV
 
  A WEEK-IN-REVIEW FEATURED REPORT
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with
tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.
Int J Clin Pract. 2011 Dec;65(12):1240-9.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine,
in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Soriano V, Arastéh K, Migrone H,  et al
Antivir Ther. 2011;16(3):339-48.
 Abstract

NVP vs EFV
 
 
A WEEK-IN-REVIEW FEATURED REPORT
 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine
clinical practice in Europe: a EuroSIDA study.
 Reekie J, Reiss P, Ledergerber B, Sedlacek D, et al
HIV Med. 2010 Aug 31
 Abstract

Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
 Harmann M, Witte S, Brust J, et al
Int J STD AIDS. 2005 Jun;16(6):404-9.
Abstract
 
Plasma HIV-1 RNA Decline Within the First Two Weeks of Treatment Is
Comparable for Nevirapine, Efavirenz, or Both Drugs Combined and Is Not
Predictive of Long-Term Virologic Efficacy: A 2NN Substudy.
 van Leth F, Huisamen CB, Badaro R, et al 
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300.
 Abstract
 
Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label
Observational Study.
 Manfredi R, Calza L, Chiodo F. 
J Acquir Immune Defic Syndr. 2004 Mar 15;35(5):492-502.
 Abstract

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in
antiretroviral-naive patients with advanced HIV infection.
 Manosuthi W, Sungkanuparph S, Vibhagool A, et al
HIV Med. 2004 Mar;5(2):105-9.
Abstract
 

  
NVP vs LPV
 
  A WEEK-IN-REVIEW FEATURED REPORT
 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine
clinical practice in Europe: a EuroSIDA study.
 Reekie J, Reiss P, Ledergerber B, Sedlacek D, et al
HIV Med. 2010 Aug 31
Abstract

Generic
 
  Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based
generic highly active antiretroviral therapy in South India.
Saghayam S, Kumarasamy N, Cecelia AJ, et al
 Clin Infect Dis. 2007 Jan 15;44(2):295-300.
Abstract
Special Populations
 
Hemophiliacs
 
  Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
 Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5
 Abstract
 
Methadone Users
 
  Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving
Nevirapine or Efavirenz.
Pelet A, Favrat B, Cavassini M, et al
 Am J Drug Alcohol Abuse. 2011 Jun 23
 Abstract
Investigator Interviews
       
  José M. Gatell, MD, PhD
 September 25, 2003

NVP Main Page  Main New/Newsworthy 

Home Page

  

 

  

Nevirapine Journal Data